Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0601-1
Abstract: SummaryBackground Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with chemotherapy. This phase I study assessed oral afatinib plus intravenous gemcitabine or docetaxel in patients with relapsed/refractory… read more here.
Keywords: combination; afatinib; gemcitabine; afatinib irreversible ... See more keywords